C. Caty-villa, Les interactions médicamenteuses. [Internet]. [cité 2016 mars 27];Disponible sur: http://slideplayer.fr/slide, 492808.

F. Puisset and . Variabilité-interindividuelle-pharmacocinétique-et-pharmacodynamique-en-oncologie, Thèse Doctorat : pharmacologie, Toulouse [Internet]. [cité 2016 févr 13]; Disponible sur: http://thesesups.ups-tlse.fr/79, 2007.

D. Bois, D. , D. Bois, and E. , A formula to estimate the approximate surface area if height and weight be known, Nutrition, vol.5, pp.303-316, 1916.

M. Sawyer and M. Ratain, Body surface area as a determinant of pharmacokinetics and drug dosing, Investigational New Drugs, vol.19, issue.2, pp.171-178, 2001.
DOI : 10.1023/A:1010639201787

E. Gehan and S. George, Estimation of human body surface area from height and weight, Cancer Chemother Rep, vol.54, pp.225-260, 1970.

D. Mitchell, N. Strydom, C. Van-graan, and W. Van-der-walt, Human surface area: Comparison of the du bois formula with direct photometric measurement, Pfl??gers Archiv, vol.43, issue.2, pp.188-90, 1971.
DOI : 10.1007/BF00587008

D. Pinkel, The use of body surface area as a criterion of drug dosage in cancer chemotherapy, Cancer Res, vol.18, pp.853-859, 1958.

S. Reagan-shaw, M. Nihal, N. Ahmad, and G. Sewell, Dose translation from animal to human studies revisited Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. FDA, 2005. [Internet]. [cité 2015 déc 31]; Disponible sur: http://www.fda.gov Chemotherapy dosing part I: scientific basis for current practice and use of body surface area, FASEB J Clin Oncol R Coll Radiol Baker SD, vol.2219, issue.12, pp.659-6123, 2007.

L. Grochow, C. Baraldi, and D. Noe, Is dose normalization to weight or body surface area useful in adults?, J Natl Cancer Inst, vol.82, pp.323-328, 1990.

H. Gurney, Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative., Journal of Clinical Oncology, vol.14, issue.9, pp.2590-611, 1996.
DOI : 10.1200/JCO.1996.14.9.2590

H. Gurney, How to calculate the dose of chemotherapy, British Journal of Cancer, vol.7, issue.8, pp.1297-302, 2002.
DOI : 10.1038/sj.bjc.6600139

A. Felici, J. Verweij, and A. Sparreboom, Dosing strategies for anticancer drugs: the good, the bad and body-surface area, European Journal of Cancer, vol.38, issue.13, pp.1677-84, 2002.
DOI : 10.1016/S0959-8049(02)00151-X

G. Paintaud, Pharmacocin??tique des anticorps monoclonaux, m??decine/sciences, vol.25, issue.12, pp.1057-62, 2009.
DOI : 10.1051/medsci/200925121057

W. Wang, E. Wang, and J. Balthasar, Monoclonal Antibody Pharmacokinetics and Pharmacodynamics, Clinical Pharmacology & Therapeutics, vol.38, issue.5, pp.548-58, 2008.
DOI : 10.1007/s00280-005-1022-3

S. Bai, K. Jorga, Y. Xin, J. D. Zheng, Y. Damico-beyer et al., A Guide to Rational Dosing of Monoclonal Antibodies, Clinical Pharmacokinetics, vol.317, issue.17, pp.119-154, 2012.
DOI : 10.2165/11596370-000000000-00000

D. Wang, S. Zhang, H. Zhao, A. Men, K. Parivar et al., Fixed dosing versus body sizebased dosing of monoclonal antibodies in adult clinical trials Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis, J Clin Pharmacol Pharm Res, vol.4923, issue.21, pp.1012-241275, 2006.

A. Garg, A. Quartino, J. Li, J. J. Wada, D. Li et al., Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors, Cancer Chemotherapy and Pharmacology, vol.49, issue.R55, pp.819-848, 2014.
DOI : 10.1007/s00280-014-2560-3

E. Chatelut and F. Puisset, The Scientific Basis of Body Surface Area???Based Dosing, Clinical Pharmacology & Therapeutics, vol.14, issue.4, pp.359-61, 2014.
DOI : 10.1111/j.1365-2125.2010.03638.x

B. Gao, H. Klumpen, and H. Gurney, Dose calculation of anticancer drugs, Expert Opinion on Drug Metabolism & Toxicology, vol.6, issue.10, pp.1307-1326, 2008.
DOI : 10.1038/bjc.1992.55

J. Baker and S. Jones, Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust, Journal of Oncology Pharmacy Practice, vol.256, issue.1, pp.1100-610, 1998.
DOI : 10.1177/107815529800400101

R. Plumridge and G. Sewell, Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy, Am J Health Syst Pharm, vol.58, pp.1760-1764, 2001.

B. Zavery, G. Marsh, S. Hennebicq, P. Secretan, L. Carrez et al., Could logarithmic dosing change the way cytotoxics are prescribed? Clinical Pharm Disponible sur: http://www.pharmaceutical-journal.com/files/rps-pjonline/pdf/cp201104_viewpoint-116.pdf 29Standard doses applied to preparations of injectable drugs and their reconstitution in the hospital: methodology and implementation] Institute for Safe Medication Practices (ISMP) List of High-Alert medications in acute care setting, J Pharm Belg, vol.30, issue.3, pp.116-11742, 2011.

J. Hecq, J. Baker, and S. Jones, Centralized intravenous additive services (CIVAS): the state of the art in 2010 Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust, Ann Pharm Fr J Oncol Pharm Pr, vol.694, issue.32, pp.30-710, 1998.

A. Gillian, Cancer Network Pharmacists Forum Dose-Banding Toolkit: How to implement Dose-Banding of chemotherapy, 2008.

L. Briz and E. , Applying dose banding to the production of antineoplastic drugs: a narrative review of the literature], Farm Hosp, vol.39, pp.210-216, 2015.

S. Williamson and C. Polwart, North of England Cancer Network (NHS) Guidelines for the dose-banding of cancer chemotherapy. 2013 [Internet]. [cité 2015 déc 18]; Disponible sur: http://www.nescn.nhs.uk/wp-content/uploadsdose-banding-guidelines- version-1_5, 2012.

J. Fouque, G. Belhabib, B. Verrière, H. Aboudagga, P. Prognon et al., Evaluation de la préparation par campagne de diffuseurs de 5-fluorouracil à partir d'une solution mère

. Congrès-du-gerpac and . Presqu-'île-de-ponant-la-grande-motte, [Internet]. [cité 2016 mars 12]; Disponible sur: https://www.scribd.com/embeds/108998235/content?start_page=1&view_mode=slideshow& access_key=key-23zv0znpe1kuy0u5dqiy 40, 2012.

P. Jenkins and R. Wallis, Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity, Journal of Oncology Pharmacy Practice, vol.332, issue.68, pp.251-256, 2010.
DOI : 10.1177/1078155209351304

C. Loboda, Standardisation des doses d'anticancéreux : enquête européenne et extension du concept aux services d'Hépato-Gastroentérologie, de pneumologie et de neurologie du CHU de Nancy. Thèse d'exercice; DES de pharmacie hospitalière

G. Loison, Thèse d'exercice; DES de pharmacie hospitalière. Le Mans, Mise en place des doses standards de chimiothérapie au centre hospitalier du Mans, 2013.

. Exemple-d-'une-molécule-onéreuse, C. Lemarignier, M. Ancel, and D. Roncalez, Congrès de la SFPO, Nantes, 2015 [Internet]. [cité 2016 mars 7]; Disponible sur: http://www.sfpo.com/wp-content/uploads, 2015.

]. Internet, S. Hennebicq, P. Secretan, L. Carrez, and J. Hecq, Présentation d'une démarche d'aide et de réflexion pour la mise en place de doses standards appliquée aux préparations et reconstitution d'injectables en milieu hospitalier]; Disponible sur: https://www.researchgate.net/profile, Journal de Pharmacie de Belgique, vol.96, pp.134-180

L. Soumoy, C. Pirlot, L. Decosta, P. Gillet, and J. Hecq, Etude préliminaire pour l'implémentation d'un dose-banding de chimiothérapie anticancéreuse, J Pharm Belg, vol.3, pp.24-35, 2015.

L. Descombes, P. Chennell, R. Chevrier, and M. Doly, Impact de deux processus de pr??parations anticip??es et du contr??le analytique sur le temps de dispensation au sein d???un centre de lutte contre le cancer, Le Pharmacien Hospitalier et Clinicien, vol.50, issue.3, pp.259-65, 2015.
DOI : 10.1016/j.phclin.2014.11.009

M. Paul, H. Standardisation-des-doses-de-chimiothérapie-À, . Mondor, C. Onconews, A. Loubière et al., 2011(4) [Internet]. [cité 2016 mars 7]; Disponible sur: http://www.cahpp.fr/wp-content/uploads, Mise en place de la préparation anticipée nominative d'anticancéreux à doses standards arrondies, pp.307-341, 2011.

S. Martignoni, G. Podilsky, B. Gay, and A. Pannatier, Interest of dose banding in the preparation of 5-FU infusors in ambulatory care European associaton of hospital pharmacists (Eahp)

F. Maclean, J. Macintyre, J. Mcdade, and D. Moyes, Dose banding of chemotherapy in the Edinburgh Cancer Centre, Pharm. J, vol.270, pp.691-694, 2003.

H. Hirte, S. Kagoma, L. Zhong, I. Collins, D. Burns et al., Dose banding of chemotherapy doses at the Juravinski Cancer Centre PP-014 Preliminary study to implement dose banding in a teaching hospital, ASCO Meet. Abstr. Eur J Hosp Pharm, vol.2421, pp.6099-55, 2006.

K. Field, A. Zelenko, S. Kosmider, K. Court, L. Ng et al., Dose rounding of chemotherapy in colorectal cancer: An analysis of clinician attitudes and the potential impact on treatment costs, Asia-Pacific Journal of Clinical Oncology, vol.27, issue.1, pp.203-212, 2010.
DOI : 10.1111/j.1743-7563.2010.01297.x

H. Reinhardt, R. Trittler, S. Wohrl, B. Grob, M. Kleber et al., Dose-banding of chemotherapy agents and its implications for hematology-oncology practice. Congrès ADKA A national survey investigating UK prescribers' opinions on chemotherapy dosing and « dose-banding », Clin Oncol R Coll Radiol, vol.21, pp.320-328, 2009.

S. Kaestner and G. Sewell, Dose-banding of carboplatin: rationale and proposed banding scheme, Journal of Oncology Pharmacy Practice, vol.37, issue.2, pp.109-126, 2007.
DOI : 10.1177/1078155207080801

S. Kaestner and G. Sewell, Chemotherapy Dosing Part II: Alternative Approaches and Future Prospects, Clinical Oncology, vol.19, issue.2, pp.99-107, 2007.
DOI : 10.1016/j.clon.2006.10.003

P. Européenne, A. Barnes, G. Douris, W. Goddard, S. Hiom et al., Recommendation of the validation of aseptic processes, Standard Protocol for Deriving and Assessment of Stability. Part 2: Aseptic Preparations (Biopharmaceuticals). NHS Pharmaceutical Quality Assurance Committee, p.2012

C. Bardin, A. Astier, A. Vulto, G. Sewell, J. Vigneron et al., Guidelines for the practical stability studies of anticancer drugs: A European consensus conference, Annales Pharmaceutiques Fran??aises, vol.69, issue.4, pp.221-252, 2011.
DOI : 10.1016/j.pharma.2011.07.002

S. Gibaud, R. Les-polymeres-et-leur-chimie-ikeda, L. Vermeulen, E. Lau, Z. Jiang et al., Laboratoire de pharmacie clinique et biotechnique Disponible sur: http://www.pharmclin.uhpnancy .fr/gibaudcours/Les%20polymeres%20et%20leur%20chimie.pdf 69 Stability of infliximab in polyvinyl chloride bags, Nancy [Internet]. Am J Health Syst Pharm, vol.69, pp.1509-1521, 2012.

S. Guirao, M. Paul, E. Jaccoulet, K. Morand, and A. Astier, Stabilité de l'infliximab en solutions diluées, Congrès de l'APHIF, 2009.

M. Disponible-sur-robert, S. Spurr-michaud, and M. Frenette, stabilis.org/FichesBiblio/3317.pdf 71

B. Young, M. Khan, T. Chapman, R. Parry, M. Connolly et al., Disponible sur: http://www.ansm.sante.fr/var/ansm_site/storage/original/application/6187b427efca64d2a15e4 96ff691158e.pdf 73 Evaluation of the physicochemical and functional stability of diluted REMSIMA(®) upon extended storage- A study compliant with NHS (UK) guidance, Agence nationale de sécurité du médicament et des produits de santé, 2013.

Y. Zhang, L. Trissel, J. Martinez, and D. Gilbert, Stability of acyclovir sodium 1, 7, and 10 mg/mL in 5% dextrose injection and 0.9% sodium chloride injection, Am J Health Syst Pharm, vol.55, pp.574-581, 1998.

D. Gupta, V. Pramar, Y. Bethea, and C. , STABILITY OF ACYCLOVIR SODIUM IN DEXTROSE AND SODIUM CHLORIDE INJECTIONS, Journal of Clinical Pharmacy and Therapeutics, vol.44, issue.6, pp.451-457, 1989.
DOI : 10.1111/j.1365-2710.1989.tb00270.x

J. Dewulf, L. Galanti, M. Godet, P. Gillet, J. Jamart et al., Long-term stability of acyclovir in 0.9% NaCl infusion polyolefin bags at 5??3??C after freeze-thaw treatment: A generic product versus the brand name, Annales Pharmaceutiques Fran??aises, vol.73, issue.2, pp.108-121, 2015.
DOI : 10.1016/j.pharma.2014.10.003

S. Kaestner and G. Sewell, Pharmacoeconomic aspects of dose-banding

. Pharm and . Eur, [cité 2016 mars 13]; Disponible sur: http://www.hospitalpharmacyeurope.com/featured-articles/pharmacoeconomic-aspects-dose- banding 78

S. Parveen, S. Kaur, S. David, J. Kenney, W. Mccormick et al., Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products, Cytotoxic Aseptic Preparations. Pharm Technol Hosp Pharm, pp.8012-8035, 2011.
DOI : 10.1016/j.vaccine.2011.08.055

S. Essai-de, 6.1). Pharmacopée européenne

. Bact, ALERT(R) 3D System for Rapid Sterility Testing of Biopharmaceutical Samples, PDA J Pharm Sci Technol, vol.66, pp.38-54, 2012.

E. Quatremare, Nutrition parentérale et maitrise du risque microbiologique: validation d'une méthode alternative pour l'essai de stérilité des mélanges nutritifs « à la carte ». Thèse d'exercice; DES de pharmacie Hospitalière, p.2014

C. Disponible-sur-pigué, J. Jeannot, E. Jumas-bilak, and M. Florent, O019 Contrôle microbiologique des mélanges de nutrition parentérale « à la carte » : comparaison d'un milieu diphasique pour hémoculture, de l'automate Bact/Alert® et de l'essai de stérilité selon la pharmacopée européenne, Nutr. Clin. Métabolisme Supplement, vol.8421, issue.2, pp.40-41, 2007.

. Jimenez, Optimisation de la production biopharmaceutique par le systeme

M. Moine, C. Ménard, D. Sankhare, G. Ventroux, V. Breteau et al., Préparation manuelle ou semi-automatisée de petits lots : quelle est la préférence du préparateur ? Congrès du GERPAC, presqu'île de Giens, 2015.

. Énerg, [cité 2016 mars 1]; Disponible sur: http://www.connaissancedesenergies.org/l- ebullition-de-l-eau-est-uniquement-liee-a-sa-temperature-121113

T. Sizer, J. Rhodes, S. Hiom, M. Oldcorne, L. Musker et al., Protocols for the integrity testing of syringes. NHS Pharmaceutical Quality Assurance Committee. 2nd Ed. 2013 [Internet]. [cité 2016 mars 1]; Disponible sur: http://www.pasg.nhs.uk/downloads.php?did=266 89, SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update, pp.376-89, 2013.

J. Hecq, M. Godet, J. Jamart, and L. Galanti, Microwave freeze-thaw technique of injectable drugs. A review from 1980 to 2014, Annales Pharmaceutiques Fran??aises, vol.73, issue.6, pp.436-477, 2015.
DOI : 10.1016/j.pharma.2015.04.009

J. Hecq, D. Vanbeckbergen, J. Jamart, and L. Galanti, Physico-chemical analysis of several injectable drug in ready-to-use infusion after microwave freeze-thaw treatment and final storage at 5??3??C, Annales Pharmaceutiques Fran??aises, vol.69, issue.5, pp.270-276, 2011.
DOI : 10.1016/j.pharma.2011.08.001

. Stabilis®, Stabilité et compatibilité des médicaments, Internet]. [cité 2016 mars

C. Disponible-sur-eiden, L. Philibert, K. Bekhtari, S. Poujol, F. Malosse et al., Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags, American Journal of Health-System Pharmacy, vol.66, issue.21, pp.1929-1962, 2009.
DOI : 10.2146/ajhp090039

P. André, S. Cisternino, A. Roy, F. Chiadmi, J. Schlatter et al., Stability of oxaliplatin in infusion bags containing 5% dextrose injection, American Journal of Health-System Pharmacy, vol.64, issue.18, pp.1950-1954, 2007.
DOI : 10.2146/ajhp060369

J. Thiesen and I. Krämer, Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags, Journal of Oncology Pharmacy Practice, vol.1, issue.4, pp.115-136, 2000.
DOI : 10.1177/107815520000600305

B. Vincke, A. Verstraeten, E. Eini, D. Mccarthy, and T. , Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers, International Journal of Pharmaceutics, vol.54, issue.3, pp.181-190, 1989.
DOI : 10.1016/0378-5173(89)90095-1

L. Galanti, M. Lebitasy, J. Hecq, J. Cadrobbi, D. Vanbeckbergen et al., Longterm stability of 5-Fluorouracil in 0.9% sodium chloride after freezing, microwave thawing, and refrigeration Stability of fluorouracil administered through four portable infusion pumps, Can J Hosp Pharm Am J Hosp Pharm, vol.6246, pp.34-82036, 1989.

M. Northcott, M. Allsopp, H. Powell, and G. Sewell, THE STABILITY OF CARBOPLATIN, DIAMORPHINE, 5-FLUOROURACIL AND MITOZANTRONE INFUSIONS IN AN AMBULATORY PUMP UNDER STORAGE AND PROLONGED ???IN-USE??? CONDITIONS, Journal of Clinical Pharmacy and Therapeutics, vol.229, issue.2, pp.123-132, 1991.
DOI : 10.1111/j.1365-2710.1991.tb00293.x

M. Stiles, L. Allen, and S. Prince, Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes, Am J Health Syst Pharm, vol.53, pp.1583-1591, 1996.

E. Rochard, G. Chapelle, S. Bouquet, D. Barthes, and P. Courtois, Stability of fluorouracil and cytarabine in ethylvinylacetate containers, J Pharm Clin, vol.9, pp.31-36, 1990.

E. Rochard, D. Barthes, and P. Courtois, Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs, Am J Hosp Pharm, vol.49, pp.619-642, 1992.

Q. Xu, Y. Zhang, and L. Trissel, Physical and Chemical Stability of Gemcitabine Hydrochloride Solutions, Journal of the American Pharmaceutical Association (1996), vol.39, issue.4, pp.509-522, 1999.
DOI : 10.1016/S1086-5802(16)30470-3

C. Beitz, T. Bertsch, D. Hannak, W. Schrammel, C. Einberger et al., Compatibility of plastics with cytotoxic drug solutions???comparison of polyethylene with other container materials, International Journal of Pharmaceutics, vol.185, issue.1, pp.113-134, 1999.
DOI : 10.1016/S0378-5173(99)00175-1